SOURCE: OmniComm Systems, Inc.

October 15, 2007 10:34 ET

OmniComm Systems, Inc. Continues to Have Success in Delivering Superior Integrated Electronic Data Capture (EDC) Solutions for Clinical Trial Research in Third Quarter 2007

Company Signs an Additional 10 New Business Deals With a Combination of New and Existing Customers to Use TrialMaster® for Electronic Data Capture

FT. LAUDERDALE, FL--(Marketwire - October 15, 2007) - OmniComm Systems, Inc. (OTCBB: OMCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 10 new business deals in Q3, totaling 35 deals for the year. Key market segments for the new business include pharmaceutical companies, including 2 Top 50 pharma company deals in the mix, biotechnology companies and contract research organizations (CROs). The increase in CRO business has been the primary catalyst for growth in Q3.

"Our CRO Preferred Program™ has been extremely successful," said Stephen Johnson, Executive Vice President of Business Development, Professional Services and Client Services and Support. "CROs are enjoying the benefits of fixed pricing, no hidden costs or fees, a dedicated hosted environment and complete training and sales and marketing support, all distinct advantages of being an OmniComm partner. Since its inception in April of this year, 17 CROs have joined the program allowing us successful sales growth through the traditionally slower summer months."

Another driving factor for new business at OmniComm is the integration of Oracle Clinical® with OmniComm's EDC solution, TrialMaster. The OC Connect™ solution from OmniComm allows clients to collect and process data within their EDC system and export the data into Oracle Clinical, allowing for a single, unified data repository. The integration also provides consistency across clinical applications by allowing companies to load all or part of their global libraries into TrialMaster. Building studies in TrialMaster can be done quickly and easily by using the same global library objects that exist in Oracle Clinical.

"Through the integration, our customers can significantly decrease the amount of time it takes to set up their clinical trials in TrialMaster by leveraging the standards that are defined in their Oracle Clinical global library," said Chris Huang, Director of New Product Development for OmniComm. "Our clients are looking for solutions that reduce the high costs traditionally associated with data integration and the OC Connect solution is just one component of our overall data integration and interoperability strategy."

2007 business deals include:

Pharmaceutical

--  24 month, Phase III, Dermatology study with 100 sites and 2132
    subjects
--  24 month, Phase III, Anti-Infective study with 50 sites and 500
    subjects
--  5 month, Phase II, Psoriasis study with 3 sites and 30 subjects
    

Biotechnology

--  15 month, Phase II, Infectious Disease study with 15 sites and  24
    subjects
--  13 month, Phase IIIb, Infectious Disease study with 10 sites and 154
    subjects
    

Contract Research Organization

--  3 month, Phase I, Urology study with 1 site and 20 subjects
--  24 month, Phase IV, Allergic Rhinitis study with 10 sites and 90
    subjects
--  8 month, Phase II, Dermatology study with 10 sites and 140 subjects
--  6 month, Phase I,  Transient Insomnia study with 6 sites and 230
    subjects
--  24 month, Phase II, Oncology study with 15 sites and 30 subjects
    

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact